
a novel non-ansamycin potent Hsp90 inhibitor with an IC50 of 3.8 nM. analogue antagonist for Hsp90. KW-2478 suppressed the binding of bRD to manner. KW-2478 indicated a potent anti-cancer activity both in clearly prevented cancer cell growth in all cell lines, with EC50 of 101-252, B-cell lymphoma, mantle cell lymphoma and multiple myeloma, respectively. growth inhibitory activity in primary CLL (n=3) and NHL (n=2) cells with